CSPG4 and melanoma: The expression in not only primary but also metastatic melanoma cells further underlines the great therapeutic potential of targeting CSPG4, especially for treatment of metastatic melanoma, which is generally associated with poor prognosis and a median survival of less than one year (9, 10, 16).